|Bid||0.00 x 1300|
|Ask||0.00 x 900|
|Day's Range||96.67 - 99.50|
|52 Week Range||96.67 - 142.60|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||20.20|
|Earnings Date||Oct 18, 2022 - Oct 24, 2022|
|Forward Dividend & Yield||1.88 (1.94%)|
|Ex-Dividend Date||Oct 13, 2022|
|1y Target Est||124.94|
Subscribe to Yahoo Finance Plus to view Fair Value for ABT
Baby formula maker Bubs Australia Ltd said on Monday it is seeking permanent access to the U.S. market after the Food and Drug Administration (FDA) spelled out how companies that have been filling a temporary shortage can become long-term suppliers. Bubs said it had lodged a letter of intent with the U.S. FDA for permanent market access to October 2025 and beyond, adding that the FDA will issue a letter of acknowledgement in response. Global infant formula manufacturers have been importing goods into the United States after the country's health regulator relaxed its import policy to address a nationwide shortage partly triggered by Abbott Laboratories' manufacturing plant in Michigan recalling some products in February.
For more than 130 years, Abbott has been known as a company that helps people live healthier lives.
Lawmakers said they expected the legislation would make formula easier to find, especially for families in the WIC supplemental-nutrition program.